Thus, inhibiting this pathway with trametinib allows chemotherapy (cisplatin/pemetrexed) to increase the CXCL10 expression and production by cancer cells, the recruitment of CD8 T cells within the tumor and the control of the tumor growth when associated with the anti-PD-1 antibody [39]. The gene discussed is CD8A; the disease is neoplasm.